A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
List view / Grid view
20 April 2016 | By Victoria White, Digital Content Producer
Emergent BioSolutions' ES425 molecule is being developed as a potential therapeutic for triple-negative breast cancer (TNBC)...
21 July 2015 | By Victoria White
Emergent BioSolutions has been awarded a BARDA contract valued at $19.7 million to develop and manufacture three Ebola monoclonal antibodies...